(Q52198890)

English

Antipsychotic drug effects in a model of schizophrenic attentional disorder: a randomized controlled trial of the effects of haloperidol on latent inhibition in healthy people.

scientific article published in December 1996

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 April 2018

http://europepmc.org/abstract/MED/8931917

Antipsychotic drug effects in a model of schizophrenic attentional disorder: a randomized controlled trial of the effects of haloperidol on latent inhibition in healthy people. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 April 2018

http://europepmc.org/abstract/MED/8931917

0 references

1 reference

based on heuristic

inferred from title

randomized controlled trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Williams JH

1

1 reference

Europe PubMed Central

PubMed publication ID

26 April 2018

http://europepmc.org/abstract/MED/8931917

Wellman NA

2

1 reference

Europe PubMed Central

PubMed publication ID

26 April 2018

http://europepmc.org/abstract/MED/8931917

Geaney DP

3

1 reference

Europe PubMed Central

PubMed publication ID

26 April 2018

http://europepmc.org/abstract/MED/8931917

Cowen PJ

4

1 reference

Europe PubMed Central

PubMed publication ID

26 April 2018

http://europepmc.org/abstract/MED/8931917

Feldon J

5

1 reference

Europe PubMed Central

PubMed publication ID

26 April 2018

http://europepmc.org/abstract/MED/8931917

Rawlins JN

6

1 reference

Europe PubMed Central

PubMed publication ID

26 April 2018

http://europepmc.org/abstract/MED/8931917

language of work or name

0 references

publication date

1 December 1996

1 reference

Europe PubMed Central

PubMed publication ID

26 April 2018

http://europepmc.org/abstract/MED/8931917

Biological Psychiatry

1 reference

Europe PubMed Central

PubMed publication ID

26 April 2018

http://europepmc.org/abstract/MED/8931917

40

1 reference

Europe PubMed Central

PubMed publication ID

26 April 2018

http://europepmc.org/abstract/MED/8931917

11

1 reference

Europe PubMed Central

PubMed publication ID

26 April 2018

http://europepmc.org/abstract/MED/8931917

1135-1143

1 reference

Europe PubMed Central

PubMed publication ID

26 April 2018

http://europepmc.org/abstract/MED/8931917

Effects of tobacco smoking, schizotypy and number of pre-exposures on latent inhibition in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

The disorder of consciousness in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Differential performance of acute and chronic schizophrenics in a latent inhibition task.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Evidence of reduced 'cognitive inhibition' in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Individual differences in schizotypy as reflected in measures of cognitive inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Recent advances in the neuropathology of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Basal ganglia and limbic system pathology in schizophrenia. A morphometric study of brain volume and shrinkage

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Context, time, and memory retrieval in the interference paradigms of Pavlovian learning

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Haloperidol enhancement of latent inhibition: Relation to therapeutic action?

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Animal models of schizophrenia: the case for LSD-25.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioral model of clinical drug action

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Bootstrap Methods: Another Look at the Jackknife

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Nonparametric estimates of standard error: The jackknife, the bootstrap and other methods

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

The latent inhibition model of schizophrenic attention disorder. Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

From an animal model of an attentional deficit towards new insights into the pathophysiology of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Amphetamine-induced disruptions of latent inhibition are reinforcer mediated: implications for animal models of schizophrenic attentional dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Effects of the neuroleptic alpha-flupenthixol on latent inhibition in aversively- and appetitively-motivated paradigms: evidence for dopamine-reinforcer interactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Patterns of cerebral blood flow in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Latent inhibition in humans: data, theory, and implications for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Latent inhibition: the effect of nonreinforced pre-exposure to the conditional stimulus.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Animal models in psychiatric research

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Animal models for schizophrenia: the hippocampally lesioned animal.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Both electrolytic and excitotoxic lesions of nucleus accumbens disrupt latent inhibition of learning in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Facilitation of the expression but not the acquisition of latent inhibition by haloperidol in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Disruption of latent inhibition by acute administration of low doses of amphetamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

A neuroleptic-like effect of ceronapril on latent inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

Latent inhibition in rats is abolished by NMDA-induced neuronal loss in the retrohippocampal region, but this lesion effect can be prevented by systemic haloperidol treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2895%2900629-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0006-3223(95)00629-X

1 reference

Europe PubMed Central

PubMed publication ID

26 April 2018

http://europepmc.org/abstract/MED/8931917

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 April 2018

http://europepmc.org/abstract/MED/8931917

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52198890&oldid=1531364796"